Long-acting CRF2 peptide agonist improves cardiac function in a rat heart failure model

Back

ESC Professional Premium Access

Long-acting CRF2 peptide agonist improves cardiac function in a rat heart failure model

Session: Experimental therapies for heart failure

Topic: Pharmacotherapy

Speaker: Mr Y. Stephan (Rouen, FR)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Mr Yohan Stephan

Rouen University Medical School, Rouen (France)

0 follower

5 more presentations in this session

The acute hemodynamic effects of sodium lactate infusion: increased cardiac output and decreased afterload in a randomized trial in pigs

Speaker: Mr O. Horsdal (Aarhus N, DK)

Non-steroidal mineralocorticoid receptor antagonist, finerenone, attenuates obesity- and hypertension-induced cardiomyocyte hypertrophy in a blood pressure-independent manner.

Speaker: Doctor K. Morikawa (Kumamoto, JP)

Therapeutic potential of pharmacological inhibition of programmed apoptosis, necroptosis, and ferroptosis in improving left ventricular function in post-myocardial infarction rats

Speaker: Doctor C. Piamsiri (Chiang Mai, TH)

Effects of vericiguat on redox signaling in cardiomyocyte

Speaker: Doctor T. Harada (Yufu City, JP)

Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the RXFP1 relaxin receptor

Speaker: Doctor J. Rosenmeier (Gothenburg, SE)

Access the full session

Experimental therapies for heart failure

Speakers: Mr Y. Stephan, Mr O. Horsdal, Doctor K. Morikawa, Doctor C. Piamsiri, Doctor T. Harada...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Long-acting CRF2 peptide agonist improves cardiac function in a rat heart failure model

About the speaker

Mr Yohan Stephan

5 more presentations in this session

The acute hemodynamic effects of sodium lactate infusion: increased cardiac output and decreased afterload in a randomized trial in pigs

Non-steroidal mineralocorticoid receptor antagonist, finerenone, attenuates obesity- and hypertension-induced cardiomyocyte hypertrophy in a blood pressure-independent manner.

Therapeutic potential of pharmacological inhibition of programmed apoptosis, necroptosis, and ferroptosis in improving left ventricular function in post-myocardial infarction rats

Effects of vericiguat on redox signaling in cardiomyocyte

Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule agonist of the RXFP1 relaxin receptor

Access the full session

Experimental therapies for heart failure

About the event

ESC Congress 2023

ESC 365 is supported by